Novo Holdings' planned $16.5B acquisition of Catalent gets EU inquiry
Carolina Rudah/iStock via Getty Images
Novo Holdings' planned $16.5 billion purchase of Catalent (NYSE:CTLT) is being probed by the European antitrust regulator.
The European Commission has set a date of Dec. 6 to decide if its analysis of the combination will move to an in-depth review, according to a posting on the regulator's website.
Catalent (CTLT) and Novo Nordisk Foundation received a request for more information from the Federal Trade Commission in May on their planned deal.
In February, Catalent agreed to be acquired by Novo Holdings for $63.50 a share. Novo Holdings will then sell three Catalent manufacturing sites to Novo Nordisk (NVO), which should help increase production of the company’s hugely popular weight-loss drug, Wegovy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10